We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
March 27, 2025
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
Crinetics announces European Medicines Agency Validation of Marketing Authorization Application and Orphan Drug Designation for paltusotine in acromegaly.
March 10, 2025
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee.
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for endocrine diseases and endocrine oncology such as:
- Acromegaly
- Carcinoid syndrome
- ACTH-dependent Cushing’s syndrome
- Congenital adrenal hyperplasia (CAH)
- Hyperparathyroidism
- Polycystic kidney disease
- Graves’ disease
- TED
- Diabetes
- Obesity
- Hyperinsulinism
Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Approved |
---|---|---|---|---|---|
Acromegaly
Congenital Adrenal Hyperplasia (CAH)
NETs and SST2-Expressing Tumors
Hyperparathyroidism
Graves' Disease, TED
Polycystic Kidney Disease
Hyperinsulinism
Diabetes, Obesity
Diabetes, Obesity
Targeted Radiotherapy for Multiple Solid-Tumors
Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Approved |
---|---|---|---|---|---|
Acromegaly
Congenital Adrenal Hyperplasia (CAH)
NETs and SST2-Expressing Tumors
Hyperparathyroidism
Polycystic Kidney Disease
Hyperinsulinism
Graves' Disease, TED
Diabetes, Obesity
Diabetes, Obesity
Targeted Radiotherapy for Multiple Solid-Tumors